Kusne Y, Mosalem OM, Quillen J, Buckner-Petty S, Muniz M, Sartor O, Johnson GB, Childs DS, Patnaik MM. Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium<sup>-177</sup> prostate-specific antigen membrane therapy. haematol [Internet]. 2025Sep.1 [cited 2025Dec.21];110(9):2187-92. Available from: https://haematologica.org/article/view/12006